October 29, 2015 (BOSTON) – Proskauer represented longtime client Frazier Healthcare Partners in closing Frazier Life Sciences VIII, L.P., a venture capital fund with total capital commitments in excess of $260 million. The offering was significantly oversubscribed and was conducted on an expedited basis, with launch to close occurring over the course of roughly two months.

Frazier Life Sciences VIII will invest exclusively in companies developing novel therapeutics. It is Frazier Healthcare Partners’ first sector-specific fund and brings the firm’s total committed capital under management to more than $2.4 billion.

Frazier Healthcare Partners is a leading provider of growth capital to health care companies. It has invested in more than 170 health care companies, with investment types ranging from company creation and venture capital to growth buyouts and leveraged recapitalizations.

Proskauer’s Private Investment Funds Group has advised Frazier Healthcare Partners in forming and closing multiple funds over the years. This deal underscores the strength of the firm’s experience and capabilities in the life sciences space.

The Proskauer team included Robin Painter, Stephen Meli, Meredith Uhl, Ryan Carpenter and Daniel Jeng (Private Investment Funds), and Jamiel Poindexter and Amanda Hellenthal (Tax).